Oncodesign: Servier lifts the exclusive worldwide license option on the program in collaboration with OPM











Photo credit © Reuters


(Boursier.com) — The pharmaceutical group Servier and Oncodesign Precision Medicine (OPM), a subsidiary ofOncodesign specialized in precision medicine, announce the lifting of the exclusive license option by Servier for their drug candidate inhibitor of the target kinase LRRK2 (Leucine-Rich-Repeat Kinase 2), resulting from their collaboration in Parkinson’s disease.

In March 2019, Servier and Oncodesign entered into a research and development collaboration on LRRK2 kinase inhibitors, derived from the Nanocyclix platform belonging to OPM, as potential therapeutic agents for Parkinson’s disease. This collaboration is based on the complementary expertise of Servier and OPM in the field of neurodegenerative diseases and kinase inhibitors. In June 2021, the two companies announced the selection of a preclinical drug candidate. Servier anticipates the start of a Phase 1 study in healthy volunteers before the end of 2022.

The exercise of the option triggers the payment by Servier of a milestone payment of 7 ME to OPM. In total, Servier could pay OPM up to 320 ME in R&D, regulatory and commercial milestone payments, to which may be added any royalties on future sales.


©2022 Boursier.com






Source link -87